Luke Sergott
Stock Analyst at Barclays
(3.39)
# 1,001
Out of 5,130 analysts
369
Total ratings
51.81%
Success rate
2.56%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Maintains: Overweight | $37 → $39 | $38.04 | +2.52% | 20 | Dec 15, 2025 | |
| RVTY Revvity | Maintains: Overweight | $105 → $115 | $103.89 | +10.69% | 12 | Dec 15, 2025 | |
| QGEN Qiagen | Maintains: Overweight | $50 → $52 | $47.25 | +10.86% | 3 | Dec 15, 2025 | |
| RGEN Repligen | Maintains: Overweight | $175 → $200 | $168.40 | +18.76% | 4 | Dec 15, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Equal-Weight | $1.5 → $2 | $2.01 | -0.50% | 6 | Dec 15, 2025 | |
| NTRA Natera | Maintains: Overweight | $230 → $270 | $235.45 | +14.67% | 6 | Dec 15, 2025 | |
| MTD Mettler-Toledo International | Maintains: Overweight | $1,600 → $1,550 | $1,491.99 | +3.89% | 4 | Dec 15, 2025 | |
| MEDP Medpace Holdings | Maintains: Underweight | $485 → $525 | $598.99 | -12.35% | 5 | Dec 15, 2025 | |
| ILMN Illumina | Maintains: Underweight | $100 → $110 | $145.55 | -24.42% | 22 | Dec 15, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Equal-Weight | $185 → $200 | $180.15 | +11.02% | 23 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $120 | $107.57 | +11.56% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $215 | $218.82 | -1.75% | 11 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $13 | $9.39 | +38.45% | 20 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $55 | $53.42 | +2.96% | 8 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $22 | $19.80 | +11.11% | 15 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $10 → $15 | $18.41 | -18.52% | 14 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $165 | $147.99 | +11.49% | 14 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $77 → $105 | $102.25 | +2.69% | 9 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $18.99 | +5.32% | 23 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $15 → $12 | $12.28 | -2.28% | 27 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $275 → $325 | $272.91 | +19.09% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $585 → $625 | $615.45 | +1.55% | 29 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $250 | $239.00 | +4.60% | 41 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $185 → $200 | $240.86 | -16.96% | 24 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $106.37 | -15.39% | 1 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $400 → $350 | $393.68 | -11.10% | 18 | Apr 10, 2025 |
Twist Bioscience
Dec 15, 2025
Maintains: Overweight
Price Target: $37 → $39
Current: $38.04
Upside: +2.52%
Revvity
Dec 15, 2025
Maintains: Overweight
Price Target: $105 → $115
Current: $103.89
Upside: +10.69%
Qiagen
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $52
Current: $47.25
Upside: +10.86%
Repligen
Dec 15, 2025
Maintains: Overweight
Price Target: $175 → $200
Current: $168.40
Upside: +18.76%
Pacific Biosciences of California
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $2
Current: $2.01
Upside: -0.50%
Natera
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $235.45
Upside: +14.67%
Mettler-Toledo International
Dec 15, 2025
Maintains: Overweight
Price Target: $1,600 → $1,550
Current: $1,491.99
Upside: +3.89%
Medpace Holdings
Dec 15, 2025
Maintains: Underweight
Price Target: $485 → $525
Current: $598.99
Upside: -12.35%
Illumina
Dec 15, 2025
Maintains: Underweight
Price Target: $100 → $110
Current: $145.55
Upside: -24.42%
ICON Public Limited Company
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $185 → $200
Current: $180.15
Upside: +11.02%
Dec 15, 2025
Maintains: Overweight
Price Target: $85 → $120
Current: $107.57
Upside: +11.56%
Dec 15, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $218.82
Upside: -1.75%
Dec 15, 2025
Maintains: Overweight
Price Target: $14 → $13
Current: $9.39
Upside: +38.45%
Dec 15, 2025
Maintains: Overweight
Price Target: $45 → $55
Current: $53.42
Upside: +2.96%
Dec 15, 2025
Maintains: Overweight
Price Target: $17 → $22
Current: $19.80
Upside: +11.11%
Dec 15, 2025
Upgrades: Equal-Weight
Price Target: $10 → $15
Current: $18.41
Upside: -18.52%
Dec 15, 2025
Upgrades: Overweight
Price Target: $165
Current: $147.99
Upside: +11.49%
Nov 21, 2025
Downgrades: Equal-Weight
Price Target: $77 → $105
Current: $102.25
Upside: +2.69%
Nov 5, 2025
Maintains: Overweight
Price Target: $19 → $20
Current: $18.99
Upside: +5.32%
Oct 30, 2025
Downgrades: Equal-Weight
Price Target: $15 → $12
Current: $12.28
Upside: -2.28%
Oct 27, 2025
Maintains: Equal-Weight
Price Target: $275 → $325
Current: $272.91
Upside: +19.09%
Oct 23, 2025
Maintains: Overweight
Price Target: $585 → $625
Current: $615.45
Upside: +1.55%
Oct 22, 2025
Maintains: Overweight
Price Target: $225 → $250
Current: $239.00
Upside: +4.60%
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $185 → $200
Current: $240.86
Upside: -16.96%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $106.37
Upside: -15.39%
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $400 → $350
Current: $393.68
Upside: -11.10%